FDA approves AstraZeneca COVID drug for people with immune problems

DMCA / Correction Notice
- Advertisement -

The Food and Drug Administration issued an emergency use authorization for the AstraZeneca COVID-19 antibody drug for people with compromised immune systems.

- Advertisement -

why it matters: medicine, evucheld, is first antibody therapy In the US, it is authorized to prevent the symptoms of coronavirus before exposure to the virus.

  • It provides long-lasting protection with a single dose and is authorized for certain adults and adolescents who are not currently infected with COVID-19 and who have not been recently exposed.
  • Currently, it is only authorized for immunocompromised people, including organ transplant recipients, blood cancer patients, and people taking immunosuppressant drugs for conditions such as rheumatoid arthritis.

What are they saying: Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, noted in a statement That vaccines were still the best defense against COVID-19.

  • “However, there are some immune-compromised individuals who may not produce an adequate immune response to COVID-19 vaccination, or who have a history of serious adverse reactions to the COVID-19 vaccine and So one can’t get it and an alternative prevention option is needed,” Cavazzoni said.
  • “Today’s action authorizes the use of a combination of two monoclonal antibodies to reduce the risk of developing COVID-19 in these individuals.”

how it works: medicine is Two monoclonal antibodies, made of laboratory-produced proteins that mimic the ability of the immune system to fight harmful pathogens such as viruses, are tixagvimab and silgavimab.

  • It is administered via two injections – one of each monoclonal antibody – in a single sitting and can provide protection for up to six months.

By numbers: Under the agreement, AstraZeneca will supply the US government with 700,000 doses of Evushield, which will be distributed proportionately across states at no cost and on a proportionate basis.

- Advertisement -


- Advertisement -

Stay on top - Get the daily news in your inbox

Recent Articles

Related Stories